创新癌症治疗比较效果(CEIT-Cancer)项目:数据库构建与审批时证据收集的原理与设计
CEIT-Cancer项目旨在构建一个模块化、灵活的系统性数据库,收录2000至2016年间FDA批准的所有新型抗癌药物和治疗性生物制品,记录其监管特征、审批文件及其中报告的所有临床试验的设计特征和治疗效果。该数据库为系统评价新型抗癌药物的获益与危害、开展比较效果研究和持续评估监管进展提供了基础。
要点
- 数据库覆盖2000-2016年FDA批准的新型抗癌药物与生物制品。
- 收集审批文件中的临床试验设计特征与治疗效果数据。
- 模块化设计支持持续更新与meta-流行病学分析。
核心结论
- 建立了覆盖17年FDA批准抗癌药物的比较效果数据库,支持系统评价获益与危害及meta-流行病学研究。
研究设计与样本
- 模块化灵活数据库,系统收集2000至2016年FDA批准的新型抗癌药物与治疗性生物制品相关数据。
- 记录监管特征,获取FDA审批文件,识别其中所有临床试验并提取设计特征与治疗效果。
临床怎么用
- 为meta-流行病学研究提供审批时证据的系统性数据基础,支持持续评估监管发展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The available evidence on the benefits and harms of novel drugs and therapeutic biologics at the time of approval is reported in publicly available documents provided by the US Food and Drug Administration (FDA). We aimed to create a comprehensive database providing the relevant information required to systematically analyze and assess this early evidence in meta-epidemiological research. METHODS: We designed a modular and flexible database of systematically collected data. We identified all novel cancer drugs and therapeutic biologics approved by the FDA between 2000 and 2016, recorded regulatory characteristics, acquired the corresponding FDA approval documents, identified all clinical trials reported therein, and extracted trial design characteristics and treatment effects. Herein, we describe the rationale and design of the data collection process, particularly the organization of the data capture, the identification and eligibility assessment of clinical trials, and the data extraction activities. DISCUSSION: We established a comprehensive database on the comparative effects of drugs and therapeutic biologics approved by the FDA over a time period of 17 years for the treatment of cancer (solid tumors and hematological malignancies). The database provides information on the clinical trial evidence available at the time of approval of novel cancer treatments. The modular nature and structure of the database and the data collection processes allow updates, expansions, and adaption for a continuous meta-epidemiological analysis of novel drugs. The database allows us to systematically evaluate benefits and harms of novel drugs and therapeutic biologics. It provides a useful basis for meta-epidemiological research on the comparative effects of innovative cancer treatments and continuous evaluations of regulatory developments.
引用
- Ladanie A, Speich B, Naudet F, et al. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. Trials. 2018. PMID: 30231912. doi:10.1186/s13063-018-2877-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。